10x Genomics’s (NASDAQ:TXG) Q2 CY2026: Strong Sales, Full-Year Outlook Slightly Exceeds Expectations
10x Genomics reported Q2 CY2026 revenue of $151 million, above analyst estimates of $146.5 million, and GAAP EPS of -$0.14 versus -$0.25 expected. Revenue declined 12.6% year over year. The company raised full-year revenue guidance to $620 million at the midpoint from $612.5 million. Operating margin was -12.9%.
How this was made
The 30-second read
Why it matters
Traders can reassess near-term expectations based on the beat and the slightly higher full-year revenue midpoint, while monitoring whether margin deterioration persists.
Market read
A modest guidance raise alongside a revenue and EPS beat is likely the primary driver for positioning, offset by worsening operating margin.
What to watch
Margin decline could signal cost structure or mix issues that may offset the revenue beat in forward estimates.
Background
The excerpt summarizes 10x Genomics Q2 performance, including revenue/EPS vs consensus and a full-year revenue guidance update.
Ticker impact
10x Genomics reported Q2 revenue of $151M vs $146.5M estimates and lifted full-year revenue guidance to $620M midpoint.
Near-term bias higher on the guidance raise, tempered by margin deterioration.
The article discloses a beat plus a specific full-year guidance midpoint increase, but also shows operating margin worsening to -12.9%.
Market effects
Biotech/life-science tools sentiment may improve modestly if investors view demand as resilient despite margin pressure.
No clear regional spillover indicated beyond US small/mid-cap growth sentiment.
Limited global relevance from the provided excerpt.
Counterpoint
The guidance lift is small and operating margin is still sharply negative, suggesting profitability risk may cap the stock reaction.
Key entities
- company10x Genomics
Reported Q2 revenue and EPS results, and raised full-year revenue guidance slightly above the prior midpoint.
